Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label mass balance and pharmacokinetic study of subcutaneous [14C]omacetaxine in relapsed/refractory hematologic malignancies or advanced solid tumors
NL-OMON40403Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2013
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of homoharringtonine in leukemia, chronic myelogenous leukemia (CML), Acute promyelocytic leukaemia (APL) and 3 more (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Pharmacokinetics of [14C]omacetaxine and metabolites. Started Oct 2013; status: active, not recruiting.
02
Drugs
homoharringtonine
03
Conditions
leukemiachronic myelogenous leukemia (CML)Acute promyelocytic leukaemia (APL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON40403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40403.